Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
646 people get NKTR articles and Market Currents by email alert.
Get email alerts on NKTR »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
Cowen Sees Nektar Outperforming Market By 30%+Notable Calls • Wed, Jun 27, 2007 -
Nektar Therapeutics: Strong Short Squeeze CandidateNotable Calls • Thu, May 10, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
7 Fast Growing Small Cap Biotech Stocks With Analyst ConfidenceZetaKap • Fri, Jul 6, 2012 -
-
-
-
5 Hedge Fund Biotech Stock Picks With Significant Short CoveringKapitall • Tue, Apr 24, 2012 -
-
-
Nektar CEO Discusses Q3 2010 Results - Earnings Call TranscriptThu, Nov 4, 2010
-
Nektar Therapeutics Q2 2010 Earnings Call TranscriptThu, Jul 29, 2010
-
Nektar Therapeutics Q1 2010 Earnings Call TranscriptThu, May 6, 2010
-
Nektar Therapeutics Q2 2009 Earnings Call TranscriptTue, Aug 4, 2009
-
Nektar Therapeutics F4Q08 and Year End 2008 Earnings Call TranscriptMon, Mar 2, 2009
-
Nektar Therapeutics, Q4 2008 Earnings Call TranscriptMon, Mar 2, 2009
-
Nektar Therapeutics Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Nektar Therapeutics Q2 2008 Earnings Call TranscriptSat, Aug 9, 2008
-
Nektar Therapeutics Q1 2008 Earnings Call TranscriptMon, May 19, 2008
-
Nektar Therapeutics Q4 2007 Earnings Call TranscriptMon, Mar 10, 2008
-
PR Newswire (May 9, 2013)
-
PR Newswire (Mar 1, 2013)
-
PR Newswire (Feb 28, 2013)
-
PR Newswire (Nov 12, 2012)
NKTR vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Our current proprietary product pipeline is comprised of... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 5:36 PM Nektar (NKTR): Q1 EPS of -$0.48 misses by $0.06. Revenue of $23M misses by $3.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 28, 5:27 PM Nektar Therapeutics (NKTR): Q4 EPS of -$0.46 misses by $0.01. Revenue of $21.1M beats by $2.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, November 13, 2012, 12:10 AM Notable earnings after Tuesday’s close: CSCO, GA, IAG, NKTR, RENN, SVM Comment! [Earnings]
- Monday, November 12, 2012, 5:35 PM Notable earnings after Tuesday’s close: CSCO, GA, IAG, NKTR, RENN, SVM Comment! [Earnings]
- Thursday, November 1, 2012, 12:10 AM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
- Wednesday, October 31, 2012, 5:35 PM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
- Thursday, August 9, 2012, 4:44 PM Nektar Therapeutics (NKTR): Q2 EPS of -$0.30 beats by $0.03. Revenue of $23.7M (+36.6% Y/Y) beats by $4M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, May 2, 2012, 6:44 PM Nektar Therapeutics (NKTR): Q1 EPS of -$0.36 misses by $0.03. Revenue of $17.9M (+58% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Wednesday, February 29, 2012, 5:15 PM Nektar Therapeutics (NKTR): Q4 EPS of -$0.33 beats by $0.14. Revenue of $15.8M (-65% Y/Y) beats by $3M. Shares +1.9% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Wednesday, April 27, 2011, 5:06 PM Nektar Therapeutics (NKTR): Q1 EPS of -$0.33 misses by $0.06. Revenue of $11M (-66% Y/Y) misses by $6M. Shares -0.10% AH. (PR) Comment! [Earnings, Healthcare]
- Wednesday, April 27, 2011, 12:10 AM Notable earnings after Wednesday's close: AFL, AKAM, ALL, ARRS, BDN, BIDU, CCI, CDNS, COG, CTXS, CYH, DDR, DRE, EBAY, EQIX, EQR, EXXI, FLEX, FTNT, GMCR, ICO, IDCC, ISIL, LNC, LOGI, LSI, NKTR, NSC, NVLS, OI, ORLY, PMTC, QGEN, SBUX, SCI, TER, TLCR, TQNT, VAR, WLL,XLNX. Comment! [Earnings]
- Tuesday, March 1, 2011, 4:21 PM Nektar Therapeutics (NKTR): Q4 EPS of -$0.24 may not be comparable with consensus of -$0.16. Revenue of $45.3M (+16% Y/Y) beats by $3.8M. Shares +2.7% AH. (PR) Comment! [Earnings]
- Tuesday, March 1, 2011, 12:10 AM Notable earnings after Tuesday's close: DNDN, MBI, MDR, NKTR, PAY, SINA, TIVO Comment! [Earnings]
-
Jim Van Meerten
NKTR - 96% Barchart technical buy signal - 15 new highs and up 26.27% in the last month - Relative strength Index 77.91% - View all 0 replies
-
- View all 0 replies
-
reachmygoals1
Nektar's(NKTR) upcoming catalysts: * NKTR-102 - Phase 2 expansion top-line data in ovarian cancer (April) * NKTR-181 - Phase 2 start - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
5 Trade Setups While Waiting For The Market To Do Something http://stk.ly/pcW4WG BEBE GMO LIOX MHGC NKTR - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES